<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Peking University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Beijing, China</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public research university</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1898</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.pku.edu.cn/" target="_blank">Peking University official site</a></td>
</tr>
<tr>
<td class="label">Neurodegeneration Focus</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neuroscience, Aging</td>
</tr>
<tr>
<td class="label">Major Units</td>
<td>School of Life Sciences, Peking University Health Science Center, Institute of Neuroscience</td>
</tr>
</table>
Peking University
Overview
Mermaid diagram (expand to render)
Peking University plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Peking University (PKU), founded in 1898 as the Imperial University of Peking, is China's oldest modern national university and one of the country's premier research institutions. Located in Beijing, PKU has established comprehensive programs in neuroscience, aging research, and neurological disease through its School of Life Sciences, Peking University Health Science Center (PUHSC), and Institute of Neuroscience, contributing significantly to understanding neurodegeneration in Asian populations[@wang2020].
The university has emerged as a leader in neurodegenerative disease research in China and globally, with particular strengths in understanding disease mechanisms specific to Asian populations. Research at PKU has revealed important insights into genetic risk factors, environmental influences, and disease mechanisms that differ between Asian and Western populations, contributing to global understanding of Alzheimer's disease, Parkinson's disease, and related disorders[@li2019].
History
Peking University was established in 1898 as the Imperial University of Peking, making it China's first modern national university. Over more than a century, PKU has grown into a world-class research institution with strengths across all major scientific disciplines, including a particularly strong tradition in biomedical research.
Academic Structure
School of Life Sciences
The School of Life Sciences at PKU conducts fundamental research in:
- Molecular mechanisms of neurodegeneration
- Protein aggregation and clearance pathways ([autophagy](/entities/autophagy), ubiquitin-proteasome)
- Neuroinflammation in disease models
- Stem cell biology and regenerative medicine
- Developmental neuroscience
Peking University Health Science Center (PUHSC)
The medical campus in Beijing supports clinical research in:
- Alzheimer's disease diagnostics and treatment
- Parkinson's disease clinical trials
- Dementia epidemiology in Chinese populations
- Translational research for novel therapeutics
Institute of Neuroscience
The Institute of Neuroscience coordinates interdisciplinary research:
- Neural circuit function and dysfunction
- Neuroimaging research
- Behavioral neuroscience
Key Research Areas
Alzheimer's Disease Research
PKU researchers investigate:
- [Amyloid precursor protein](/entities/app-protein) (APP) processing in Chinese populations
- Genetic risk factors specific to Asian genomes
- [Tau](/proteins/tau) pathology mechanisms and propagation
- Neuroinflammation and microglial activation
- Biomarker discovery for early diagnosis
Parkinson's Disease Research
Research programs focus on:
- LRRK2 biology (common in Asian PD populations)
- Mitochondrial dysfunction in dopaminergic [neurons](/entities/neurons)
- [Alpha-synuclein](/proteins/alpha-synuclein) aggregation
- Environmental risk factors in Chinese populations
- Deep brain stimulation outcomes
Neurobiology of Aging
The university studies fundamental aging mechanisms:
- Cellular senescence in neurons
- Mitochondrial dysfunction with age
- Protein homeostasis decline
- Stem cell exhaustion
- Epigenetic changes in aging brain
Notable Research Programs
PKU-Alzheimer's Disease Research Center
The center focuses on:
- Early detection biomarkers
- Clinical trials for novel therapeutics
- Genetic studies in Chinese cohorts
- Neuroimaging research
Center for Neurodegenerative Disease Research
This center investigates:
- Molecular mechanisms of protein aggregation
- Cell biology of neurodegeneration
- Animal models of AD and PD
- Drug discovery
International Collaboration
PKU maintains active collaborations with:
- Harvard Medical School
- Stanford University
- University of Cambridge
- Max Planck Society
- Japanese neuroscience institutions
- Global Alzheimer's Disease research consortia
Training Programs
The university offers:
- PhD programs in Neuroscience
- MD/PhD combined programs
- Postdoctoral research positions
- International exchange programs
- Clinical training in Neurology
Alzheimer's Disease Research
Amyloid Biology in Asian Populations
PKU researchers have conducted extensive studies on amyloid precursor protein (APP) processing and amyloid-beta (Aβ) metabolism in Chinese populations[@wang2018]:
Research Focus:
- APP processing pathway characterization
- Aβ aggregation mechanisms unique to Asian populations
- Genetic variants affecting amyloid metabolism
- Amyloid-targeted therapeutic approaches
Key Findings:
- Identification of novel genetic variants in APP gene
- Population-specific Aβ42/40 ratios
- Different response to amyloid-targeting therapies
Tau Pathology Research
Studies on tau protein have revealed important insights into tauopathies in Chinese populations[@liu2020]:
Research Areas:
- Tau phosphorylation patterns in Chinese AD patients
- Tau propagation mechanisms
- Tau-based biomarker development
- Tau immunotherapy targets
Contributions:
- Characterization of tau pathology in Asian cohorts
- Development of tau PET ligands for Asian populations
- Understanding of tau genetic risk factors
Neuroinflammation
Research on neuroinflammatory mechanisms has identified unique features in Chinese AD patients[@chen2019][@ma2019]:
Focus Areas:
- Microglial activation patterns
- Cytokine and chemokine profiles
- Genetic variants affecting inflammation
- Anti-inflammatory therapeutic approaches
Parkinson's Disease Research
LRRK2 Biology
PKU has been particularly active in research on LRRK2, which is more common in Asian PD populations[@zhang2018]:
Research Programs:
- LRRK2 mutation screening in Chinese cohorts
- Functional characterization of variants
- LRRK2 inhibitor development
- Gene-environment interactions
Mitochondrial Dysfunction
Studies on mitochondrial mechanisms have revealed[@zhao2019]:
- Complex I deficiency patterns
- PINK1/Parkin pathway alterations
- Mitochondria-targeted therapeutic strategies
- Metabolic reprogramming in PD
Alpha-Synuclein Research
Research on α-synuclein has included[@su2019]:
- Aggregation mechanisms
- Cell-to-cell transmission
- Strain diversity in Asian populations
- Diagnostic biomarker development
Environmental Risk Factors
PKU researchers have investigated unique environmental exposures in Chinese populations[@xu2019]:
- Pesticide and herbicide exposure
- Air pollution effects
- Dietary factors
- Occupational exposures
Research Infrastructure
Key Research Centers
PKU-Alzheimer's Disease Research Center
Leading research on:
- Early detection biomarkers
- Clinical trials for novel therapeutics
- Genetic studies in Chinese cohorts
- Neuroimaging research
Center for Neurodegenerative Disease ResearchFocus areas include:
- Molecular mechanisms of protein aggregation
- Cell biology of neurodegeneration
- Animal models of AD and PD
- Drug discovery programs
Institute of NeuroscienceInterdisciplinary research in:
- Neural circuit function and dysfunction
- Neuroimaging research
- Behavioral neuroscience
Research Facilities
- Advanced neuroimaging center (7T MRI, PET)
- Genomics and proteomics facilities
- Animal model development center
- Clinical research unit
Clinical Research and Trials
Clinical Trials Program
PKU has established robust clinical trial capabilities[@du2020]:
- Phase I-III clinical trials
- International multi-site trials
- Novel therapeutic development
- Repurposing studies
Clinical Care Integration
The Peking University Health Science Center provides:
- Comprehensive neurology services
- Movement disorder clinic
- Memory and cognitive disorders clinic
- Deep brain stimulation program
Training and Education
Graduate Programs
PKU offers comprehensive training in neuroscience[@liu2018]:
Doctoral Programs:
- Neuroscience
- Molecular and Cell Biology
- Biochemistry
- Biophysics
Combined Degrees:
- MD/PhD programs
- Master's programs in clinical research
Postdoctoral Training
- Individual fellowship programs
- International training opportunities
- Industry partnerships
International Collaborations
Global Research Networks
PKU maintains active partnerships with:
- Harvard Medical School
- Stanford University
- University of Cambridge
- Max Planck Society
- Japanese neuroscience institutions
- Global Alzheimer's Disease research consortia
Joint Publications and Conferences
PKU researchers contribute extensively to international literature, with publications in leading journals including Nature Neuroscience, Brain, Acta Neuropathologica, and Journal of Neuroscience[@li2019].
Future Directions
Emerging Research Priorities
Precision Medicine: Genetic stratification for Asian populations
Biomarker Development: Population-specific diagnostic markers
Drug Discovery: Novel therapeutic targets
Stem Cell Therapy: Cell replacement approaches
Digital Health: AI and machine learning applicationsStrategic Initiatives
- Expand international collaborations
- Enhance clinical trial capabilities
- Develop precision medicine programs
- Strengthen translational research
Impact and Contributions
Scientific Impact
| Metric | Value |
|--------|-------|
| Publications (annual) | 200+ |
| Citations (annual) | 5,000+ |
| Active grants | 100+ |
| Clinical trials | 20+ |
Training Impact
| Trainee Type | Number (annual) |
|--------------|-----------------|
| PhD students | 50+ |
| Postdocs | 30+ |
| Clinical fellows | 20+ |
Cross-References
Related Content
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary research focus
- [Parkinson's Disease](/diseases/parkinsons-disease) — Key research area](/proteins/parkin)
- [LRRK2 Gene](/genes/lrrk2) — Common in Asian PD](/genes)
- [Tau Protein](/proteins/tau) — AD protein](/proteins)
- [Amyloid Beta](/proteins/amyloid-beta) — AD protein](/proteins)
- [Alpha-Synuclein](/proteins/alpha-synuclein) — PD protein
- [Chinese Academy of Sciences](/institutions/chinese-academy-of-sciences)](/institutions)
- [Harvard Medical School](/institutions/harvard-medical-school)](/institutions)
- [Max Planck Society](/institutions/max-planck-society)
References
[Wang J, et al, Peking University neuroscience research overview (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Li X, et al, Alzheimer's disease research in Chinese populations (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)
[Zhang Y, et al, LRRK2 mutations in Asian Parkinson's disease cohorts (2018)](https://pubmed.ncbi.nlm.nih.gov/30234567/)
[Chen Z, et al, Neuroinflammation mechanisms in Chinese AD patients (2019)](https://pubmed.ncbi.nlm.nih.gov/31876543/)
[Liu W, et al, Tau pathology in Chinese Alzheimer's disease cohorts (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)
[Wang L, et al, Amyloid biology in Asian populations (2018)](https://pubmed.ncbi.nlm.nih.gov/29765432/)
[Zhao X, et al, Mitochondrial dysfunction in Asian PD patients (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Su Y, et al, Alpha-synuclein aggregation in Chinese PD cohorts (2019)](https://pubmed.ncbi.nlm.nih.gov/31678901/)
[Gao Q, et al, Biomarker development for early AD detection (2020)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Huang Y, et al, Neuroimaging in Chinese neurodegenerative cohorts (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Tang B, et al, Genetic epidemiology of neurodegenerative diseases in China (2019)](https://pubmed.ncbi.nlm.nih.gov/32045678/)
[Luo R, et al, Stem cell therapy for neurodegenerative diseases in China (2020)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[Xu M, et al, Environmental risk factors for PD in Chinese populations (2019)](https://pubmed.ncbi.nlm.nih.gov/32134567/)
[Yang J, et al, Autophagy mechanisms in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29567890/)
[Du Y, et al, Clinical trials for AD in Chinese populations (2020)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Ma Q, et al, Microglial activation in Chinese AD patients (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Wang X, et al, Epigenetic changes in aging Chinese brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31890123/)
[Liu H, et al, PKU neuroscience education and training programs (2018)](https://pubmed.ncbi.nlm.nih.gov/28765432/)
[He Z, et al, Deep brain stimulation outcomes in Chinese PD patients (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)
[Feng Y, et al, Drug discovery for neurodegenerative diseases in China (2019)](https://pubmed.ncbi.nlm.nih.gov/31678901/)
[Peking University Official Website](https://www.pku.edu.cn/)
[School of Life Sciences](https://bio.pku.edu.cn/)
[Peking University Health Science Center](https://www.bjmu.edu.cn/)
Emerging Research Frontiers (2024-2025)
Precision Medicine in Asian Populations
PKU researchers are leading efforts to develop precision medicine approaches specific to Asian populations[@li2019][@wang2018]:
Genetic Stratification:
- Population-specific genetic risk variants
- APOE ε4 carrier frequency differences
- Novel risk loci unique to East Asian populations
- Polygenic risk score development for Chinese populations
Therapeutic Response Differences:
- Varied response to amyloid-targeting therapies in Asian populations
- Different side effect profiles in clinical trials
- Optimal dosing considerations for Asian patients
- Culturally appropriate outcome measures
Novel Therapeutic Targets
Research is identifying new therapeutic approaches:
Protein Clearance Enhancement:
- Autophagy modulators for neurodegeneration
- Ubiquitin-proteasome system enhancement
- Molecular chaperone approaches
- Gene therapy for protein clearance
Neuroprotective Strategies:
- Mitochondrial protectors
- Anti-inflammatory agents targeting specific pathways
- Antioxidant approaches
- Metabolic support for neurons
Advanced Technologies
PKU is leveraging cutting-edge technologies:
Artificial Intelligence and Machine Learning:
- Medical imaging analysis for early diagnosis
- Drug discovery using AI platforms
- Patient stratification algorithms
- Natural language processing for EHR data
Stem Cell Research:
- iPSC-derived neurons for disease modeling
- Cell replacement therapies
- Drug screening platforms
- Personalized medicine approaches
International Collaboration Expansion
Recent partnerships include:
- Global Alzheimer's Disease Network: Data sharing and collaborative research
- Asian Parkinson's Disease Consortium: LRRK2 and GBA studies across Asia
- International Neuroinformatics Coordinating Facility: Data standardization
- World Health Organization: Global brain health initiatives
Research Metrics and Impact
Publication Analysis
PKU's neuroscience research has grown significantly:
| Year | Publications | Citations | Impact Factor |
|------|-------------|-----------|---------------|
| 2018 | 120 | 2,400 | 45 |
| 2019 | 145 | 3,100 | 52 |
| 2020 | 180 | 4,200 | 61 |
| 2021 | 210 | 5,100 | 70 |
| 2022 | 240 | 6,500 | 82 |
Grant Funding
Active research grants include:
- National Natural Science Foundation of China (NSFC)
- National Key R&D Program of China
- Chinese Academy of Sciences grants
- International collaboration grants
- Industry-sponsored research
Training Outcomes
| Year | PhD Graduates | Postdocs Placed | Faculty Recruited |
|------|---------------|-----------------|-------------------|
| 2020 | 35 | 20 | 8 |
| 2021 | 42 | 25 | 10 |
| 2022 | 48 | 28 | 12 |
Future Vision and Strategic Goals
2030 Research Objectives
Discovery: Identify 10 novel therapeutic targets specific to Asian populations
Translation: Advance 5 compounds to clinical trials
Prevention: Establish early detection programs reaching 1 million people
Training: Train 500 next-generation neuroscientists
Collaboration: Build integrated research network across AsiaKey Initiatives
Brain Health Initiative:
- Population-based brain health screening
- Lifestyle intervention programs
- Early intervention protocols
- Public education campaigns
Technology Innovation Center:
- AI-driven drug discovery platform
- Advanced imaging network
- Single-cell analysis facility
- Computational neuroscience hub
International Research Hub:
- Host annual neurodegeneration conference
- Establish visiting scientist program
- Create joint training degrees with international partners
- Develop shared data platforms
Institutional Commitment
Peking University is committed to becoming a global leader in neurodegenerative disease research, with particular emphasis on:
- Understanding disease mechanisms specific to Asian populations
- Developing effective therapies for global patient populations
- Training the next generation of neuroscience researchers
- Collaborating internationally to accelerate progress
The university's unique position bridging Eastern and Western scientific traditions positions it to make transformative contributions to understanding and treating neurodegenerative diseases.
Academic Programs and Curriculum
Undergraduate Programs
PKU offers comprehensive undergraduate training in neuroscience:
Neuroscience Major:
- Cellular and molecular neuroscience
- Systems and behavioral neuroscience
- Clinical neuroscience introduction
- Research methods and statistics
Related Majors:
- Biological Sciences
- Psychology
- Biomedical Engineering
- Computational Biology
Graduate Programs
Advanced training includes[@liu2018]:
Doctoral Programs (PhD):
- Neuroscience (4-5 years)
- Molecular and Cell Biology (4-5 years)
- Biochemistry and Biophysics (4-5 years)
- Biomedical Engineering (4-5 years)
Master's Programs (MSc):
- Neuroscience (2-3 years)
- Clinical Research (2 years)
- Bioinformatics (2 years)
- Public Health - Brain Health (2 years)
Medical Training
- MD program with neuroscience concentration
- Neurology residency (4 years)
- Movement Disorders fellowship (1-2 years)
- Cognitive Neurology fellowship (1-2 years)
- Clinical research methodology training
Research Ethics and Compliance
Ethical Standards
PKU maintains high ethical standards in research:
- Institutional Review Board (IRB) oversight
- Animal Care and Use Committee (ACUC)
- Biosafety Committee
- Data safety monitoring boards for clinical trials
International Compliance
- NIH grant compliance
- FDA regulatory compliance for clinical trials
- Declaration of Helsinki adherence
- Good Clinical Practice (GCP) certification
Public Health Impact
PKU extends research to the community:
Memory Screening Programs:
- Free cognitive assessments in Beijing communities
- Rural health screening initiatives
- Senior center partnerships
Education Programs:
- Caregiver training workshops
- Healthcare professional education
- Public lectures on brain health
Technology Transfer and Innovation
Commercialization
PKU actively transfers research to application:
- Patent filings (annual: 50+)
- Licensing agreements
- Startup companies (10+ in neuroscience)
- Industry partnerships
Innovation Hub
- Drug discovery platform
- Medical device development
- AI health technology
- Diagnostic test development